Skip to main content

Table 1 The prevalence of HPV infection by different characteristics from 2015 to 2019

From: Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China

 

Positive cases

Prevalence (%)

95% CI for all samples

2015 (n = 252)

2016 (n = 1900)

2017 (n = 2728)

2018 (n = 5907)

2019 (n = 13,079)

Infection feature

        

1

3213

13.46

13.03–13.89

80 (31.75%)

314 (16.53%)

413 (15.14%)

733 (12.41%)

1673 (12.79%)

2

863

3.62

3.37–3.85

34 (13.49%)

106 (5.58%)

109 (4.00%)

196 (3.32%)

418 (3.20%)

3

248

1.04

0.91–1.16

13 (5.16%)

24 (1.26%)

38 (1.39%)

49 (0.83%)

124 (0.95%)

4

97

0.41

0.32–0.48

7 (2.78%)

14 (0.74%)

12 (0.44%)

18 (0.30%)

46 (0.35%)

5

40

0.17

0.11–0.21

3 (1.19%)

7 (0.37%)

7 (0.26%)

7 (0.12%)

16 (0.12%)

6

16

0.07

0.03–0.10

3 (1.19%)

3 (0.16%)

2 (0.07%)

3 (0.05%)

5 (0.04%)

≥ 2

1276

5.35

5.06–5.63

62 (24.60%)

158 (8.32%)

169 (6.20%)

276 (4.67%)

611 (4.67%)

Type of infection

        

Single HR

2307

9.67

9.29–10.04

58 (23.02%)

225 (11.84%)

301 (11.03%)

555 (9.40%)

1168 (8.93%)

Single LR

906

3.80

3.55–4.03

22 (8.73%)

89 (4.68%)

112 (4.11%)

178 (3.01%)

505 (3.86%)

HR + HR

474

1.99

1.80–2.16

15 (5.95%)

58 (3.05%)

69 (2.53%)

102 (1.73%)

230 (1.76%)

HR + LR

707

2.96

2.74–3.17

42 (16.67%)

87 (4.58%)

85 (3.12%)

154 (2.61%)

339 (2.59%)

LR + LR

95

0.40

0.31–0.47

5 (1.98%)

13 (0.68%)

15 (0.55%)

20 (0.34%)

42 (0.32%)

Vaccine genotype

        

2v

776

3.25

3.03–3.48

23 (9.13%)

89 (4.68%)

106 (3.89%)

195 (3.30%)

363 (2.78%)

4v

1213

5.08

4.80–5.36

57 (22.62%)

165 (8.68%)

168 (6.16%)

269 (4.55%)

554 (4.24%)

9v

2487

10.42

10.03–10.81

103 (40.87%)

280 (14.74%)

329 (12.06%)

600 (10.16%)

1175 (8.98%)

Non-vaccine HR-HPV

1837

7.70

7.36–8.03

56 (22.22%)

201 (10.58%)

235 (8.61%)

430 (7.28%)

915 (7.00%)

Back to article page

Virology Journal

ISSN: 1743-422X